Cargando…

Lipoprotein(a)—60 Years Later—What Do We Know?

Lipoprotein(a) (Lp(a)) molecule includes two protein components: apolipoprotein(a) and apoB100. The molecule is the main transporter of oxidized phospholipids (OxPL) in plasma. The concentration of this strongly atherogenic lipoprotein is predominantly regulated by the LPA gene expression. Lp(a) is...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasławska, Anna, Tomasik, Przemysław J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605347/
https://www.ncbi.nlm.nih.gov/pubmed/37887316
http://dx.doi.org/10.3390/cells12202472
_version_ 1785127051104092160
author Pasławska, Anna
Tomasik, Przemysław J.
author_facet Pasławska, Anna
Tomasik, Przemysław J.
author_sort Pasławska, Anna
collection PubMed
description Lipoprotein(a) (Lp(a)) molecule includes two protein components: apolipoprotein(a) and apoB100. The molecule is the main transporter of oxidized phospholipids (OxPL) in plasma. The concentration of this strongly atherogenic lipoprotein is predominantly regulated by the LPA gene expression. Lp(a) is regarded as a risk factor for several cardiovascular diseases. Numerous epidemiological, clinical and in vitro studies showed a strong association between increased Lp(a) and atherosclerotic cardiovascular disease (ASCVD), calcific aortic valve disease/aortic stenosis (CAVD/AS), stroke, heart failure or peripheral arterial disease (PAD). Although there are acknowledged contributions of Lp(a) to the mentioned diseases, clinicians struggle with many inconveniences such as a lack of well-established treatment lowering Lp(a), and common guidelines for diagnosing or assessing cardiovascular risk among both adult and pediatric patients. Lp(a) levels are different with regard to a particular race or ethnicity and might fluctuate during childhood. Furthermore, the lack of standardization of assays is an additional impediment. The review presents the recent knowledge on Lp(a) based on clinical and scientific research, but also highlights relevant aspects of future study directions that would approach more suitable and effective managing risk associated with increased Lp(a), as well as control the Lp(a) levels.
format Online
Article
Text
id pubmed-10605347
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106053472023-10-28 Lipoprotein(a)—60 Years Later—What Do We Know? Pasławska, Anna Tomasik, Przemysław J. Cells Review Lipoprotein(a) (Lp(a)) molecule includes two protein components: apolipoprotein(a) and apoB100. The molecule is the main transporter of oxidized phospholipids (OxPL) in plasma. The concentration of this strongly atherogenic lipoprotein is predominantly regulated by the LPA gene expression. Lp(a) is regarded as a risk factor for several cardiovascular diseases. Numerous epidemiological, clinical and in vitro studies showed a strong association between increased Lp(a) and atherosclerotic cardiovascular disease (ASCVD), calcific aortic valve disease/aortic stenosis (CAVD/AS), stroke, heart failure or peripheral arterial disease (PAD). Although there are acknowledged contributions of Lp(a) to the mentioned diseases, clinicians struggle with many inconveniences such as a lack of well-established treatment lowering Lp(a), and common guidelines for diagnosing or assessing cardiovascular risk among both adult and pediatric patients. Lp(a) levels are different with regard to a particular race or ethnicity and might fluctuate during childhood. Furthermore, the lack of standardization of assays is an additional impediment. The review presents the recent knowledge on Lp(a) based on clinical and scientific research, but also highlights relevant aspects of future study directions that would approach more suitable and effective managing risk associated with increased Lp(a), as well as control the Lp(a) levels. MDPI 2023-10-17 /pmc/articles/PMC10605347/ /pubmed/37887316 http://dx.doi.org/10.3390/cells12202472 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pasławska, Anna
Tomasik, Przemysław J.
Lipoprotein(a)—60 Years Later—What Do We Know?
title Lipoprotein(a)—60 Years Later—What Do We Know?
title_full Lipoprotein(a)—60 Years Later—What Do We Know?
title_fullStr Lipoprotein(a)—60 Years Later—What Do We Know?
title_full_unstemmed Lipoprotein(a)—60 Years Later—What Do We Know?
title_short Lipoprotein(a)—60 Years Later—What Do We Know?
title_sort lipoprotein(a)—60 years later—what do we know?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605347/
https://www.ncbi.nlm.nih.gov/pubmed/37887316
http://dx.doi.org/10.3390/cells12202472
work_keys_str_mv AT pasławskaanna lipoproteina60yearslaterwhatdoweknow
AT tomasikprzemysławj lipoproteina60yearslaterwhatdoweknow